SEC Stock Data Quick Answer agilon health, inc. reported Cash and Equivalents of $173.71 million for fiscal year 2025. agilon health, inc. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $173.71M -7.7% 2024 $188.23M +75.0% 2023 $107.57M -76.9% 2022 $465.30M -55.3% 2021 $1.04B +873.9% 2020 $106.80M — Quarterly Cash and Equivalents Quarter … Read more
Quick Answer agilon health, inc. reported Total Assets of $1.27 billion for fiscal year 2025. agilon health, inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $1.27B -26.7% 2024 $1.73B -0.4% 2023 $1.74B +2.6% 2022 $1.70B +7.0% 2021 $1.59B +255.4% 2020 $446.36M — Quarterly Total Assets Quarter Ending Total Assets YoY … Read more
Quick Answer agilon health, inc. reported Net Income of -$391.35 million for fiscal year 2025. agilon health, inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$391.35M -50.4% 2024 -$260.15M +0.9% 2023 -$262.60M -146.4% 2022 -$106.55M +73.8% 2021 -$406.49M -576.9% 2020 -$60.05M +78.7% 2019 -$282.59M — Quarterly Net Income Quarter Ending … Read more
Quick Answer agilon health, inc. reported Revenue (ASC 606) of $5.93 billion for fiscal year 2025. agilon health, inc. Revenue (ASC 606) — Annual History Fiscal Year Revenue (ASC 606) YoY Change 2025 $5.93B -2.1% 2024 $6.06B +40.4% 2023 $4.32B +80.7% 2022 $2.39B +57.0% 2021 $1.52B +24.9% 2020 $1.22B +53.4% 2019 $794.41M — Quarterly Revenue … Read more
Quick Answer agilon health, inc. reported Total Revenue of $5.93 billion for fiscal year 2025. agilon health, inc. Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $5.93B -2.1% 2024 $6.06B +40.4% 2023 $4.32B +80.7% 2022 $2.39B +57.0% 2021 $1.52B +24.9% 2020 $1.22B +53.4% 2019 $794.41M — Quarterly Total Revenue Quarter Ending … Read more
Quick Answer agilon health, inc. reported Total Revenue of $5.93 billion for fiscal year 2025. agilon health, inc. — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue $5.93B-2.1% $6.06B+40.4% $4.32B+80.7% $2.39B+57.0% $1.52B+24.9% $1.22B+53.4% Revenue (ASC 606) $5.93B-2.1% $6.06B+40.4% $4.32B+80.7% $2.39B+57.0% $1.52B+24.9% $1.22B+53.4% Net Income -$391.35M-50.4% -$260.15M+0.9% -$262.60M-146.4% -$106.55M+73.8% -$406.49M-576.9% -$60.05M+78.7% … Read more
Quick Answer AGIOS PHARMACEUTICALS, INC. reported Shares Outstanding of 58.45 million shares for fiscal year 2025. AGIOS PHARMACEUTICALS, INC. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 58.45M +2.3% 2024 57.16M +2.2% 2023 55.95M +1.6% 2022 55.04M +1.3% 2021 54.33M -21.6% 2020 69.29M +1.3% 2019 68.40M +17.5% 2018 58.22M +19.2% 2017 … Read more
Quick Answer AGIOS PHARMACEUTICALS, INC. reported Operating Income of -$472.13 million for fiscal year 2025. AGIOS PHARMACEUTICALS, INC. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$472.13M -10.9% 2024 -$425.74M -8.7% 2023 -$391.49M -0.6% 2022 -$389.05M -2.8% 2021 -$378.42M -12.7% 2020 -$335.92M -6.2% 2019 -$316.27M +12.7% 2018 -$362.48M -13.0% 2017 -$320.79M … Read more
Quick Answer AGIOS PHARMACEUTICALS, INC. reported R&D Expense of $339.54 million for fiscal year 2025. AGIOS PHARMACEUTICALS, INC. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $339.54M +12.7% 2024 $301.29M +1.9% 2023 $295.53M +5.6% 2022 $279.91M +8.9% 2021 $256.97M +16.4% 2020 $220.81M +3.1% 2019 $214.26M -37.2% 2018 $341.32M +16.6% 2017 $292.68M … Read more
Quick Answer AGIOS PHARMACEUTICALS, INC. reported Stockholders Equity of $1.19 billion for fiscal year 2025. AGIOS PHARMACEUTICALS, INC. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $1.19B -22.6% 2024 $1.54B +90.0% 2023 $811.02M -26.3% 2022 $1.10B -14.8% 2021 $1.29B +223.4% 2020 $399.50M -37.6% 2019 $640.53M -6.8% 2018 $687.54M +83.1% 2017 $375.50M … Read more